Novartis MS and COVID-19 Study
Health and Safety Comes First In Our Clinical Trials
With over 25 years of work providing compassionate patient care in an effort to save lives, our goal is to be your first choice for all your medical research studies. From screening tests to clinical trial development, we implement real-world medical studies.
What Is Novartis MS and COVID-19 Study?
Multiple sclerosis is a central nervous system disorder that is characterized by myelin deterioration and damage in the brain, spinal cord, and optic nerves. There are many different clinical symptoms, such as cognitive impairment, discomfort, and issues with movement. The causes of MS are still unknown, but our understanding of the condition is growing, making treatment options more effective. Despite the availability of various disease-modifying treatments, our Novartis MS and COVID-19 study aims to check all the benchmarks of clinical trials. To prevent the disability from getting worse, this research study involves an investigational drug that can enhance long-term outcomes for RMS patients. People with MS will receive a study drug (ofatumumab) that can also produce an immune response to the COVID-19 vaccine.
Become a Big Factor in the Advancement of Patient Care
We carefully choose our staff to help meet your health needs and administer extensive clinical procedures to create solutions for tomorrow’s medicine. Whether you are working on a therapy, participating in a trial. or dealing with a problem to complete your study, our medical professionals can assist you with the execution and management of your clinical trial.
The Importance of Novartis MS and COVID-19 Study
These studies involve the use of brand-new medications and drug combinations as investigational treatments, as well as innovative strategies for their administration. We go through an extended and rigorous testing process before starting the trials. In addition to making sure they’re safe and effective, this will greatly help in discovering better treatments.
Are You Qualified for the Novartis MS and COVID-19 Study?
Approximately 88 Americans with relapsing MS are being contacted to participate in this study. You may be eligible for this volunteer research study if you are between the ages of 18 and 55. You must also have been diagnosed with relapsing MS and are beginning or currently receiving treatment with ofatumumab, interferon, or glatiramer acetate. Ofatumumab is a drug used to treat persons with relapsing types of Multiple Sclerosis (MS) by injecting it subcutaneously (under the skin).
Also, to be qualified for the study, you must:
Support the Ever-Evolving Medical Research Study
At Bradenton Research Center, we contribute unique medical research studies in a range of clinical trial procedures and other cutting-edge medical techniques. Our team pays close attention to our study’s needs, including the safety of our patients, our various medications, and volunteers. We also carry out the program’s objectives to become your go-to medical research center for clinical development across a broad spectrum of patient care. Contact us today to learn more.